# ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)

> **NCT00535730** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 473 (actual)

## Conditions studied

- Herpes Zoster
- Pneumococcal Infection

## Interventions

- **BIOLOGICAL:** Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™
- **BIOLOGICAL:** Comparator: placebo (concomitant-vaccine matched)
- **BIOLOGICAL:** Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23

## Key facts

- **NCT ID:** NCT00535730
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 473 (ACTUAL)
- **Last updated:** 2017-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00535730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00535730, "ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00535730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*